CLINICAL & PIPELINE·Drug Approval
Actavis Labs FL Inc.'s Ramelteon Generic: Navigating Labeling Updates and Market Access for Insomnia Treatment
Actavis Labs FL Inc. secured its initial generic approval for RAMELTEON (ANDA091610) in August 2015, followed by significant labeling updates in 2020 and 2023. This highlights the ongoing regulatory demands for generic manufacturers and the strategic importance of maintaining product compliance and supply chain efficiency in the competitive melatonin receptor agonist market for insomnia.
90-Day Activity